These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24345256)

  • 1. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications.
    Martin A; Godman B; Miranda J; Tilstone J; Saleem N; Olsson E; Acosta A; Restrepo L; Bennie M
    J Comp Eff Res; 2014 Jan; 3(1):41-51. PubMed ID: 24345256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
    Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE
    Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries.
    Bucsics A; Godman B; Burkhardt T; Schmitzer M; Malmström RE
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):809-19. PubMed ID: 23252361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?
    Bennie M; Bishop I; Godman B; Campbell S; Miranda J; Finlayson AE; Gustafsson LL
    Qual Prim Care; 2013; 21(1):7-15. PubMed ID: 23735629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.
    Hesse U; Godman B; Petzold M; Martin A; Malmström RE
    Appl Health Econ Health Policy; 2013 Dec; 11(6):677-85. PubMed ID: 24105097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future.
    Vončina L; Strizrep T; Godman B; Bennie M; Bishop I; Campbell S; Vlahović-Palčevski V; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):469-79. PubMed ID: 21831028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries.
    Godman B; Bucsics A; Burkhardt T; Schmitzer M; Wettermark B; Wieninger P
    Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):199-207. PubMed ID: 20384566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescribing trends and drug budget impact of the ARBs in the UK.
    Blak BT; Mullins CD; Shaya FT; Simoni-Wastila L; Cooke CE; Weir MR
    Value Health; 2009; 12(2):302-8. PubMed ID: 18647253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.
    Godman B; Bishop I; Finlayson AE; Campbell S; Kwon HY; Bennie M
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):469-82. PubMed ID: 23977975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.
    McGinn D; Godman B; Lonsdale J; Way R; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):73-85. PubMed ID: 20121565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Getting better value from the NHS drug budget.
    Moon JC; Flett AS; Godman BB; Grosso AM; Wierzbicki AS
    BMJ; 2010 Dec; 341():c6449. PubMed ID: 21169320
    [No Abstract]   [Full Text] [Related]  

  • 12. Modifying prescribing behaviour of angiotensin receptor blockers by selectively rescinding managerial prior authorization requirements for losartan.
    Kahan NR; Chinitz DP; Blackman S; Waitman DA; Vardy DA
    Br J Clin Pharmacol; 2011 Dec; 72(6):997-1001. PubMed ID: 21689138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in the utilization of venlafaxine after the introduction of generics in Sweden.
    Godman B; Persson M; Miranda J; Skiöld P; Wettermark B; Barbui C; Gustafsson LL
    Appl Health Econ Health Policy; 2013 Aug; 11(4):383-93. PubMed ID: 23754677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescribing behaviour in general practice: the impact of promoting therapeutically equivalent cheaper medicines.
    Roberts SJ; Bateman DN; Smith JM
    Br J Gen Pract; 1997 Jan; 47(414):13-8. PubMed ID: 9115786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
    Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE
    J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.
    Belsey JD
    J Med Econ; 2011; 14(5):553-61. PubMed ID: 21707445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history.
    Zeng W; Gustafsson LL; Bennie M; Finlayson AE; Godman B
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):157-69. PubMed ID: 25348709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications.
    Moon JC; Godman B; Petzold M; Alvarez-Madrazo S; Bennett K; Bishop I; Bucsics A; Hesse U; Martin A; Simoens S; Zara C; Malmström RE
    Front Pharmacol; 2014; 5():219. PubMed ID: 25339902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002.
    Stafford RS; Furberg CD; Finkelstein SN; Cockburn IM; Alehegn T; Ma J
    JAMA; 2004 Jan; 291(1):54-62. PubMed ID: 14709576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescribing efficiency of proton pump inhibitors in China: influence and future directions.
    Zeng W; Finlayson AE; Shankar S; de Bruyn W; Godman B
    BMC Health Serv Res; 2015 Jan; 15():11. PubMed ID: 25609265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.